UG United Guardian Inc

United-Guardian, Inc. (NASDAQ:UG) announced today the financial results for the second quarter and first half of 2023. Sales for the six-month period ended June 30th decreased from $7,518,535 in 2022 to $5,220,623 in 2023. Net income decreased from $1,544,789 ($0.34 per share) to $1,217,175 ($0.26 per share). Second quarter sales decreased from $3,626,177 to $2,650,299, with net income decreasing from $633,324 ($0.14 per share) to $461,094 ($0.10 per share).

Donna Vigilante, President of United-Guardian, stated, “The sales decrease for both the second quarter and the first six months of 2023 was primarily due to a decrease in sales of our cosmetic ingredients, which was partially offset by an increase in sales of Renacidin®, the Company’s principal pharmaceutical product, which increased by 7%. The distributor responsible for marketing our Lubrajel® line of cosmetic ingredients in China experienced decreased demand due to increased competition in China from lower-priced competitive products, especially those from Asian producers, along with slow post-COVID economic recovery in China. In addition, customers are maintaining lower inventory levels and changing to just-in-time inventory management, which negatively impacted our sales. We are evaluating various options to increase our sales both in China and in other markets, and are continuing to work closely with our marketing partners to develop new strategies to remain competitive while growing our market share. We are hopeful that these efforts, along with China’s re-opening progress, will result in an increase in sales going forward.”

United-Guardian is a manufacturer of cosmetic ingredients, pharmaceuticals, and medical lubricants.

	Contact:	Donna Vigilante
		(631) 273-0900
		dvigilante@u-g.com

NOTE: This press release contains both historical and "forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements about the company’s expectations or beliefs concerning future events, such as financial performance, business prospects, and similar matters, are being made in reliance upon the “safe harbor” provisions of that Act. Such statements are subject to a variety of factors that could cause our actual results or performance to differ materially from the anticipated results or performance expressed or implied by such forward-looking statements. For further information about the risks and uncertainties that may affect the company’s business please refer to the company's reports and filings with the Securities and Exchange Commission.

Financial Results for the Three and Six Months Ended June 30, 2023 and 2022

STATEMENTS OF INCOME (unaudited)

		THREE MONTHS ENDED JUNE 30,					SIX MONTHS ENDED JUNE 30,
		2023			2022			2023			2022
Net sales	$	2,650,299		$	3,626,177		$	5,220,623		$	7,518,535
Costs and expenses:
Cost of sales		1,429,407			1,693,753			2,523,002			3,403,870
Operating expenses		574,093			620,229			1,092,039			1,166,978
Research and development expense		128,729			112,266			255,688			243,932
Total costs and expenses		2,132,229			2,426,248			3,870,729			4,814,780
Income from operations		518,070			1,199,929			1,349,894			2,703,755
Other income (expense):
Investment income		54,950			58,860			102,582			99,410
Net gain (loss) gain on marketable securities		7,479			(460,278	)		80,180			(853,938	)
Total other income (expense)		62,429			(401,418	)		182,762			(754,528	)
Income before provision for income taxes		580,499			798,511			1,532,656			1,949,227
Provision for income taxes		119,405			165,187			315,481			404,438
Net income	$	461,094		$	633,324		$	1,217,175		$	1,544,789
Earnings per common share
(basic and diluted)	$	0.10		$	0.14		$	0.26		$	0.34
Weighted average shares
(basic and diluted)		4,594,319			4,594,319			4,594,319			4,594,319

Additional financial information can be found on the company’s web site at www.u-g.com.